Clinical and economic value of sofosbuvir-based regimens in the treatment of chronic hepatitis C in Spain.

ABSTRACT:

Background

The treatment of chronic hepatitis C virus (HCV) with direct-acting antivirals has undergone a spectacular revolution and added significant value to healthcare systems and patients. The aim of the study was to evaluate the efficiency and value of Sofosbuvir (SOF)-based regimens for a target population of 85,959 chronic HCV patients treated in Spain during 2015-2019, compared to previous therapeutic strategies (peginterferon/ and ribavirin in double/triple therapy with telaprevir or boceprevir).

Methods

A previously developed lifetime Markov model was adapted to simulate the disease HCV evolution. In SOF-based regimens, all patients (100%) were treated regardless with sustained virological response (SVR) of 93-98%, obtained from real-world data. In previous therape

SUBMITTER: Esteban R 

PROVIDER: S-EPMC9714855 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature